Objective: To evaluate the effect of intravitreal bevacizumab on visual acuity (VA) and central retinal thickness (CRT) in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
Design: Retrospective review.
Participants: The study included 42 patients with ME secondary to BRVO who received intravitreal injections of bevacizumab in 2 referral-based retinal practices in Vancouver, B.C., between November 2005 and July 2006.
Methods: We performed a retrospective review of consecutive patients with ME secondary to BRVO. All of the patients in this study had nonischemic BRVOs. Patients were all treated with at least 1 bevacizumab injection and were seen at 6- to 8-week intervals for VA testing. Most of the patients also underwent optical coherence tomography (OCT) 2 months and 6 months after treatment. VA and OCT measurements at each follow-up time point were compared with the baseline values.
Results: A total of 42 eyes from 42 patients with ME secondary to BRVO were reviewed. The mean VA improved from 20/280 at baseline to 20/180 at first follow-up session (p < 0.04; average follow-up = 42 days) and remained at a similar level, 20/170, through the eighth follow-up session (p < 0.04; average follow-up = 356). The CRT was reduced from a mean of 451 microm (388-512 microm) at baseline to 358 microm (298-418 microm) at 2 months (p < 0.02) and to 400 microm (335-465 microm) at 6 months postinjection (p < 0.068).
Conclusions: We found a significant improvement in VA and CRT in patients with ME secondary to BRVO after intravitreal bevacizumab injection(s). No complications or serious side effects were observed. Intravitreal bevacizumab appears to have an emerging role as either a primary or an adjuvant treatment modality in the setting of ME secondary to BRVO.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3129/i09-040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Untargeted Metabolomic Study of Patients with Macular Edema Secondary to Retinal Vein Occlusion in Aqueous Humor.
Clin Ophthalmol
January 2025
Department of Ophthalmology, Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Purpose: The aim of this study was to identify metabolic biomarkers and investigate the metabolic changes associated with aqueous humor in retinal vein occlusion macular edema (RVO-ME).
Methods: Aqueous humor (AH) samples were collected from patients, including those diagnosed with central retinal vein occlusion macular edema (CRVO-ME), branch retinal vein occlusion macular edema (BRVO-ME), and a control group undergoing cataract surgery. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was utilized to analyze the metabolomic profiles in aqueous humor.
Visual and anatomical failure of anti-VEGF therapy for retinal vascular diseases: a survival analysis of real-world data.
Eye (Lond)
December 2024
NIHR Biomedical Research Centre At Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, UK.
Importance: Predicting undesirable outcomes following anti-VEGF initiation in macular oedema is critical for effective clinical decision-making and optimised care.
Objective: To estimate the time to undesirable events in diabetic macular oedema (DMO), central and branch vein occlusions (CRVO and BRVO) after appropriate loading doses with either ranibizumab or aflibercept and identified baseline predictors of negative outcome.
Design, Setting, Participants: A retrospective cohort study of 3277 patients (N = 2107 in DMO, N = 413 in CRVO and N = 757 in BRVO) collected over a 10-year period, in a large UK tertiary centre.
Impact of anti-VEGF treatment-free interval during the first year on 5-year outcomes in eyes with branch retinal vein occlusion.
Eur J Ophthalmol
November 2024
Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Article Synopsis
- - The study investigates how the longest treatment-free interval (TFI) between anti-VEGF injections affects visual acuity and the recurrence of macular edema in patients with branch retinal vein occlusion (BRVO) over five years.
- - It included 60 patients with an average age of nearly 72, finding that 72% experienced recurrence of macular edema, with significant predictors being TFI and initial visual acuity.
- - The results suggest that longer TFIs lead to worse visual outcomes and higher rates of macular edema recurrence, indicating the need for more frequent injections in cases of severe BRVO.
Baseline Choroidal Blood Flow Imbalance as a Predictive Factor for Macular Edema Recurrence Secondary to Branch Retinal Vein Occlusion.
Diagnostics (Basel)
October 2024
Department of Ophthalmology, Toho University Sakura Medical Center, 564-1, Shimoshizu, Sakura 285-8741, Japan.
Article Synopsis
- This study assesses how choroidal blood flow (CBF) and choroidal thickness (CT) can predict if macular edema will return in patients with a specific type of eye condition (BRVO) after receiving treatment.
- Sixteen patients were treated with an injection and monitored for changes in CBF and CT over a year using specialized imaging techniques.
- Results showed that thicker CT in affected areas initially dropped after one week, while CBF remained steady; however, an imbalance in CBF was linked to how many injections were later needed, suggesting it could help predict recurrence of macular edema.
Branch retinal vein occlusion and peripheral nonperfusion associated with astrocytic hamartoma of the optic nerve head in a patient with tuberous sclerosis.
Retin Cases Brief Rep
October 2024
Ophthalmology, Oregon Health & Science University, Portland, OR.
Article Synopsis
- The case reports on a patient with tuberous sclerosis complex (TSC) who developed branch retinal vein occlusion (BRVO) leading to retinal neovascularization (NV) and vitreous hemorrhage due to an astrocytic hamartoma (AH) located at the optic nerve head.
- The study utilized electronic health records and advanced imaging techniques like fundus photography, fluorescein angiography, and optical coherence tomography (OCT) to analyze the patient's condition and identify the contributing factors.
- The findings suggest that BRVO and its complications can pose serious risks to vision in patients with AH related to TSC, highlighting the usefulness of OCT in detecting and monitoring these retinal issues.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!